Abstract: The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R1, R2, R6 and R6? are independently selected from H, (C1-C8)alkyl, unsaturated (C2-C8)hydrocarbon, and (C3-C6)cycloalkyl, being these groups optionally substituted; R3 is hydrogen or halogen; R4 is selected from H, (C1-C8)alkyl, unsaturated (C2-C8)hydrocarbon, (C3-C6)cycloalkyl, (C6-C12)aryl, and (C5-C12)heteroaryl, being these groups optionally substituted; and R5 is selected from (C3-C28)alkyl, unsaturated (C3-C28)hydrocarbon, (C6-C12)aryl, and (C5-C12)heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications.

Abstract: The invention relates to compounds having formula (I) wherein A is selected from the group consisting of: a) optionally substituted (C1-C8) alkyl; b) optionally substituted (C3-C6) cycloalkyl; c) optionally substituted (C6-C14) aryl; d) optionally substituted (C6-C14) heteroaryl; e) C(O)—(C6-C14) aryl, in which group (C6-C14) aryl is optionally substituted; f) C(O)—(C6-C14) heteroaryl, in which group (C6-C14) heteroaryl is optionally substituted; g) CH(OH)—(C6-C14) aryl, in which group (C6-C14) aryl is optionally substituted; and h) CH(OH)—(C6-C14) heteroaryl, in which group (C6-C14) heteroaryl is optionally substituted. The invention also relates to methods for the production of said compounds, to pharmaceutical and veterinary compositions comprising said compounds and to the therapeutic uses thereof, such as for the prevention and/or treatment of dry eye syndrome, vaginal dryness and/or burning mouth syndrome.

Abstract: The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R1, R2, R6 and R6? are independently selected from H, (C1-C8)alkyl, unsaturated (C2-C8)hydrocarbon, and (C3-C6)cycloalkyl, being these groups optionally substituted; R3 is hydrogen or halogen; R4 is selected from H, (C1-C8)alkyl, unsaturated (C2-C8)hydrocarbon, (C3-C6)cycloalkyl, (C6-C12)aryl, and (C5-C12)heteroaryl, being these groups optionally substituted; and R5 is selected from (C3-C28)alkyl, unsaturated (C3-C28)hydrocarbon, (C6-C12)aryl, and (C5-C12)heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications.

Abstract: Compounds of Formula (I) able to modulate Store Operated Calcium Entry (SOCE). The disclosure also relates to the use of compounds of formula (I) for treatment of pathological conditions in which SOCE modulation might be beneficial, such as neglecting disorders linked to loss- or gain-of-function STIM1/Orai1 mutations, allergic disorders, pain, inflammatory diseases, autoimmune diseases or disorders, cancer and other proliferative diseases, neurodegenerative disorders, myelodysplastic syndromes, haematological diseases, cardiovascular diseases, degenerative diseases of the musculoskeletal system, liver diseases and disorders, kidney diseases, type I diabetes, graft rejection, graft-versus-host disease, allogeneic or xenogeneic transplantation, thyroiditis and viral infections.

Abstract: Compounds of Formula (I) able to modulate Store Operated Calcium Entry (SOCE). The disclosure also relates to the use of compounds of formula (I) for treatment of pathological conditions in which SOCE modulation might be beneficial, such as neglecting disorders linked to loss- or gain-of-function STIM1/Orai1 mutations, allergic disorders, pain, inflammatory diseases, autoimmune diseases or disorders, cancer and other proliferative diseases, neurodegenerative disorders, myelodysplastic syndromes, haematological diseases, cardiovascular diseases, degenerative diseases of the musculoskeletal system, liver diseases and disorders, kidney diseases, type I diabetes, graft rejection, graft-versus-host disease, allogeneic or xenogeneic transplantation, thyroiditis and viral infections.

Abstract: The invention relates to compounds having formula (I) wherein A is selected from the group consisting of: a) optionally substituted (C1-C8) alkyl; b) optionally substituted (C3-C6) cycloalkyl; c) optionally substituted (C6-C14) aryl; d) optionally substituted (C6-C14) heteroaryl; e) C(O)—(C6-C14) aryl, in which group (C6-C14) aryl is optionally substituted; f) C(O)—(C6-C14) heteroaryl, in which group (C6-C14) heteroaryl is optionally substituted; g) CH(OH)—(C6-C14) aryl, in which group (C6-C14) aryl is optionally substituted; and h) CH(OH)—(C6-C14) heteroaryl, in which group (C6-C14) heteroaryl is optionally substituted. The invention also relates to methods for the production of said compounds, to pharmaceutical and veterinary compositions comprising said compounds and to the therapeutic uses thereof, such as for the prevention and/or treatment of dry eye syndrome, vaginal dryness and/or burning mouth syndrome.

Abstract: Compounds of formula (I): able to inhibit nicotinamide phosphoribosyltransferase. The disclosure also relates to the use of compounds of formula (I) for treatment of pathological conditions in which NAMPT inhibition might be beneficial, such as acute and chronic inflammation, cancer and metabolic disorders.